Sichuan Sunnyhope Pharmaceutical Co. Ltd.

Main objective To observe the in vivo kinetics of donepezil hydrochloride orally disintegrating tablets after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and evaluate the bioequivalence of donepezil hydrochloride orally disintegrating tablets (Aricept® D) produced by Eisai Co., Ltd. as the reference preparation. Secondary objective To observe the safety of donepezil hydrochloride orally disintegrating tablets (test preparation) and Aricept® D (reference preparation) in healthy humans.